Krisja Vermeylen
Director/Board Member presso MORPHOSYS AG
Patrimonio netto: 211 019 $ in data 29/02/2024
Profilo
Krisja Vermeylen is on the board of MorphoSys AG.
In her past career she held the position of General Manager of Novo Nordisk SA (Belgium), Senior Manager-Product at Pharmacia & Upjohn and Senior Vice President-People & Organisation at Novo Nordisk A Vice President & General Manager at Novo Nordisk Pharma GmbH and Vice President-Europe West, France & BeLux at Novo Nordisk SAS (both are subsidiaries of Novo Nordisk A).
She received a graduate degree and a doctorate from the University of Antwerp.
Partecipazioni note in società pubbliche
Società | Data | Numero di azioni | Valorizzazione | Data di valutazione |
---|---|---|---|---|
MORPHOSYS AG
0.01% | 16/02/2024 | 3 000 ( 0.01% ) | 211 019 $ | 29/02/2024 |
Posizioni attive di Krisja Vermeylen
Società | Posizione | Inizio |
---|---|---|
MORPHOSYS AG | Director/Board Member | 01/01/2017 |
Precedenti posizioni note di Krisja Vermeylen
Società | Posizione | Fine |
---|---|---|
Diaverum AB
Diaverum AB Medical/Nursing ServicesHealth Services Diaverum AB engages in the provision of renal care to patients with chronic kidney disease (CKD). It offers hemodialysis, peritoneal dialysis, and kidney transplant. The company was founded by Nils Alwall in 1991 and is headquartered in Malmo, Sweden. | Director/Board Member | 31/12/2023 |
NOVO NORDISK A/S | Human Resources Officer | 01/01/2018 |
Novo Nordisk Pharma GmbH
Novo Nordisk Pharma GmbH Pharmaceuticals: MajorHealth Technology Novo Nordisk Pharma GmbH manufacturers and distributes pharmaceutical products. It offers pharmaceutical products for diabetes, menopause, growth hormones and blood clotting which treats chronic diseases: hemophilia, growth disorders and obesity. The company was founded in 1991 and is headquartered in Mainz, Germany. | Corporate Officer/Principal | 01/01/2015 |
Novo Nordisk SAS
Novo Nordisk SAS Pharmaceuticals: MajorHealth Technology Novo Nordisk SAS manufactures pharmaceutical drugs. It produces and sells medicines for the treatment of diabetes, haemophilia, and hormonal disease. The company was founded in 1959 and is headquartered in Paris, France. | Corporate Officer/Principal | 01/01/2013 |
Novo Nordisk SA (Belgium) | Corporate Officer/Principal | 01/01/2002 |
Formazione di Krisja Vermeylen
University of Antwerp | Graduate Degree |
Esperienze
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
Società quotate in Borsa | 2 |
---|---|
NOVO NORDISK A/S | Health Technology |
MORPHOSYS AG | Health Technology |
Aziende private | 5 |
---|---|
Novo Nordisk Pharma GmbH
Novo Nordisk Pharma GmbH Pharmaceuticals: MajorHealth Technology Novo Nordisk Pharma GmbH manufacturers and distributes pharmaceutical products. It offers pharmaceutical products for diabetes, menopause, growth hormones and blood clotting which treats chronic diseases: hemophilia, growth disorders and obesity. The company was founded in 1991 and is headquartered in Mainz, Germany. | Health Technology |
Novo Nordisk SAS
Novo Nordisk SAS Pharmaceuticals: MajorHealth Technology Novo Nordisk SAS manufactures pharmaceutical drugs. It produces and sells medicines for the treatment of diabetes, haemophilia, and hormonal disease. The company was founded in 1959 and is headquartered in Paris, France. | Health Technology |
Diaverum AB
Diaverum AB Medical/Nursing ServicesHealth Services Diaverum AB engages in the provision of renal care to patients with chronic kidney disease (CKD). It offers hemodialysis, peritoneal dialysis, and kidney transplant. The company was founded by Nils Alwall in 1991 and is headquartered in Malmo, Sweden. | Health Services |
Novo Nordisk SA (Belgium) | |
Pharmacia & Upjohn
Pharmacia & Upjohn Pharmaceuticals: MajorHealth Technology Pharmacia & Upjohn is a Belgian company that manufactures pharmaceutical products. The private company is based in Brussels, Belgium. | Health Technology |